The Harmony Outcomes CVOT assessed the cardiovascular safety of albiglutide in patients with type 2 diabetes and vascular disease. This module details the study outcomes.
Harmony Outcomes
Harmony Outcomes
Harmony Outcomes
Harmony Outcomes: study design
Harmony Outcomes: primary and secondary outcomes
Harmony Outcomes: baseline characteristics (1/2)
Harmony Outcomes: baseline characteristics (2/2)
Harmony Outcomes: medical history at baseline
Harmony Outcomes: CV medication at baseline
Harmony Outcomes: glucose-lowering medication at baseline
Harmony Outcomes
Harmony Outcomes: primary outcome 3P-MACE (time to first occurrence of CV death, MI or stroke)
Harmony Outcomes: components of 3P-MACE
Harmony Outcomes: CV death
Harmony Outcomes: MI
Harmony Outcomes: stroke
Harmony Outcomes: CV outcomes
Harmony Outcomes: 3P-MACE across types of CV disease at baseline
Harmony Outcomes: 3P-MACE by HF status at baseline
Harmony Outcomes: 3P-MACE by baseline glucose-lowering medication